{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-6TB9AXI0/92486f65-b026-4f9f-b608-8b3d27cbab50/PDF","dcterms:extent":"692 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-6TB9AXI0/bce9000e-65f9-40c0-a7e3-0904bad6fbca/TEXT","dcterms:extent":"45 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-6TB9AXI0","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2024","dc:creator":["Ahlin Grabnar, Pegi","Gosenca Matjaž, Mirjam"],"dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:75"},{"@xml:lang":"sl","#text":"str. 94-104"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:196197635","URN:URN:NBN:SI:doc-6TB9AXI0"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"biological medicinal products"},{"@xml:lang":"sl","#text":"Biološka zdravila"},{"@xml:lang":"en","#text":"monoclonal antibodies"},{"@xml:lang":"sl","#text":"monoklonska protitelesa"},{"@xml:lang":"en","#text":"peptides"},{"@xml:lang":"sl","#text":"peptidi"},{"@xml:lang":"en","#text":"subcutaneous application"},{"@xml:lang":"sl","#text":"subkutana aplikacija"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Subkutana dostava terapevtskih proteinov in peptidov| Subcutaneous delivery of therapeutic proteins and peptides|"},"dc:description":[{"@xml:lang":"sl","#text":"The intensive development in the field of biological active substances, which are characterized by high specificity, improved therapeutic efficiency and fewer adverse effects, is reflected in the rapidly growing number of biological medicinal products on the market. Recently, the subcutaneous application of biological medicines has become a valuable alternative to intravenous administration for many diseases. The reasons for this are manifold and are primarily related to the numerous benefits for both the patient and the healthcare system, with the possibility of self-injection in the home environment being one of the most important. The article presents biological medicinal products with therapeutic peptides and proteins from the point of view of subcutaneous application. Thus, the development in the field of therapeutic peptides is moving towards delivery systems for subcutaneous application (polymeric microparticles, implants, and in situ gelling polymer solutions and liquid crystals), that allow sustained release for up to several months. Subcutaneous injection of high doses of monoclonal antibodies can be achieved by highly concentrated formulations with appropriate viscosity or by applying a larger volume of solution using modern containers/devices. In parallel, great progress has been made in the use of recombinant human hyaluronidase, which temporarily modifies the subcutaneous tissue so that a larger volume of solution can be applied"},{"@xml:lang":"sl","#text":"Intenziven razvoj na področju učinkovin biološkega izvora, za katere je značilna visoka specifičnost, izboljšana terapevtska učinkovitost ter manj neželenih učinkov, se odraža v hitro naraščajočem številu bioloških zdravil na trgu. V zadnjem obdobju je subkutana aplikacija bioloških zdravil postala dragocena alternativa intravenski aplikaciji pri številnih boleznih. Razlogi so večplastni in primarno vezani na številne prednosti tako za bolnika kot zdravstveni sistem, med njimi pa je ključna možnost samoinjiciranja v domačem okolju. V prispevku so predstavljena biološka zdravila s terapevtskimi peptidi in proteini z vidika subkutane aplikacije. Tako na področju terapevtskih peptidov razvoj poteka v smeri dostavnih sistemov za subkutano aplikacijo (polimerni mikrodelci, implantati ter polimerne raztopine in tekoči kristali, ki gelirajo in situ), ki omogočajo podaljšano sproščanje zdravilne učinkovine tudi do nekaj mesecev. Subkutano injiciranje visokih odmerkov monoklonskih protiteles pa je možno doseči s pomočjo visokokoncentriranih formulacij z ustrezno viskoznostjo ali z aplikacijo večjega volumna raztopine s pomočjo sodobnih vsebnikov/naprav. Vzporedno je bil velik napredek dosežen z uporabo rekombinantne človeške hialuronidaze, ki prehodno lokalno spremeni podkožje in s tem omogoči aplikacijo večjega volumna raztopine"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-6TB9AXI0","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-6TB9AXI0"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-6TB9AXI0/92486f65-b026-4f9f-b608-8b3d27cbab50/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-6TB9AXI0/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-6TB9AXI0"}}}}